相关实验视频
Updated: Jun 18, 2025

11:18
Direct Drug Delivery to Kidney via the Renal Artery
Published on: April 17, 2021
7.2K
抗凝药治疗功能不全主题:复杂情况中的抗凝药
Anna L Parks1, Scott M Stevens2, Scott C Woller2
1Division of Hematology & Hematologic Malignancies, Department of Internal Medicine, University of Utah, United States of America.
Thrombosis research
|August 2, 2024
概括
慢性病 (CKD) 的抗凝固药治疗需要仔细考虑. 本综述总结了当前的数据,并为CKD患者的抗凝药管理提供了一个框架,平衡风险和益处.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 患有功能障碍的患者通常需要抗凝药治疗心房动和静脉血栓栓塞等疾病.
- 在晚期慢性病 (CKD) 中管理抗凝固药物存在挑战,因为血栓和出血风险增加.
研究的目的:
- 审查CKD患者抗凝剂的现有数据.
- 建议在日益增长的CKD患者全球人口中为抗凝药提供决策框架.
主要方法:
- 对CKD抗凝剂的临床试验和观察数据的系统审查.
- 对抗凝血剂在CKD各个阶段的风险 (血栓和出血) 和益处的分析.
主要成果:
- 已经制定了轻度CKD的指导方针.
- 严重的CKD的数据正在演变,新兴的试验和新型药物显示出潜在的可能性.
- 在晚期的CKD中,出血和血栓的风险都增加了.
结论:
- 在CKD中,抗凝血的决定必须是个性化的,平衡血栓和出血风险.
- 需要一个结构化的方法来指导各种CKD人群的抗凝固疗法.
- 为了在严重的CKD中找到最佳的抗凝策略,需要进一步的研究.
相关概念视频
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
659
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
659
Renal Failure: Dose Adjustments
77
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
77
Factors Affecting Renal Clearance: Renal Impairment
69
Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
69
Antihypertensive Drugs: Direct Renin Inhibitors
521
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
521
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
413
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
413

